What we deliver
Valuation projects are often time-limited assignments with predefined deliverables. Our methodology is algorithm assisted, by our proprietary valuation software, to calculate a risk-adjusted net present valuation that is matched against comparable benchmarks related to deals and valuations of similar companies. Projects are executed in a proven format combining interactive client workshops with analysis of data collected from primary and secondary sources. Final deliveries are often used in negotiations, investment decision-support material or presentation for key stakeholders.
Some past questions from our clients include:
What is a reasonable valuation of our phase 2 candidate?
How can we expect the valuation of our asset to differ if we out-license it in a preclinical stage or after a clinical proof-of-concept?
What resource allocation between our five assets result in the highest projected return on investment in two to four years?
How much should we be willing to pay to in-license a phase 2 candidate?
What has been the valuation of comparable deals of preclinical assets?
How would a label extension strategy into different lines of therapy affect the current valuation of our asset?
Asset portfolio valuation of key Asian markets
An emerging pharma client needed to obtain a valuation of its highly important drug candidates in key Asian markets before negotiating a major deal with a top-tier Chinese pharma company.
Investment negotiation support to value phase 2 asset in lung cancer
The management of an oncology company with an ongoing clinical phase 2 trial needed an independent valuation base for one of its key assets for a meeting with an interested venture capitalist.